for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Crispr Therapeutics AG

CRSP.OQ

Latest Trade

47.70USD

Change

-0.63(-1.30%)

Volume

43,252

Today's Range

47.67

 - 

48.67

52 Week Range

22.23

 - 

53.90

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
48.33
Open
48.41
Volume
43,252
3M AVG Volume
10.13
Today's High
48.67
Today's Low
47.67
52 Week High
53.90
52 Week Low
22.23
Shares Out (MIL)
54.66
Market Cap (MIL)
2,641.84
Forward P/E
-12.51
Dividend (Yield %)
--

Next Event

Q3 2019 CRISPR Therapeutics AG Earnings Release

Latest Developments

More

Crispr Therapeutics Posts Q2 Loss Per Share Of $1.01

Vertex Expands Collaboration With CRISPR Therapeutics, Acquires Exonics Therapeutics

Crispr Therapeutics Reports Q1 Results, Provides Business Update

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Crispr Therapeutics AG

CRISPR Therapeutics AG is a Switzerland-based gene-editing company. It focuses on the development of transformative gene-based medicines for serious diseases. The Company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The Company has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The Company has business operations in London and the United Kingdom, as well as research and development operations in the United States.

Industry

Biotechnology & Drugs

Contact Info

Baarerstrasse 14

+41.41.5613277

http://www.crisprtx.com/

Executive Leadership

Rodger Novak

Chairman of the Board of Directors, President, Founder

Samarth Kulkarni

Chief Executive Officer, Director

Kala Subramanian

Senior Vice President - Strategic Development and Operations

Megan Wherry Menner

Senior Vice President of Human Resources

Sven Ante Lundberg

Chief Scientific Officer

Key Stats

2.31 mean rating - 16 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

0.150

2017

-1.710

2018

-3.440

2019(E)

-3.865
Price To Earnings (TTM)
--
Price To Sales (TTM)
1,995.35
Price To Book (MRQ)
7.03
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-50.26
Return on Equity (TTM)
-47.30

Latest News

BRIEF-CRISPR Therapeutics And Viacyte Present Positive In Vitro Data Towards A Potential Immune-Evasive Cell Replacement Therapy For Diabetes At EASD 2019

* CRISPR THERAPEUTICS AND VIACYTE PRESENT POSITIVE IN VITRO DATA TOWARDS A POTENTIAL IMMUNE-EVASIVE CELL REPLACEMENT THERAPY FOR DIABETES AT EASD 2019 Source text for Eikon: Further company coverage:

BRIEF-Crispr Therapeutics AG May Offer And Sell From Time To Time Its Common Shares Having Aggregate Offering Price Of Up To $200 Million

* CRISPR THERAPEUTICS AG - MAY OFFER AND SELL FROM TIME TO TIME ITS COMMON SHARES HAVING AGGREGATE OFFERING PRICE OF UP TO $200 MILLION

BRIEF-Crispr Therapeutics Posts Q2 Loss Per Share Of $1.01

* CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS

GSK signs up gene-editing pioneers in drug discovery alliance

* GSK, University of California set up lab for genomics research

Vertex Pharmaceuticals expands into Duchenne gene therapy with new deals

Vertex Pharmaceuticals Inc said http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20190606:nBw4wRKsa on Thursday it would acquire privately held Exonics Therapeutics for an upfront payment of $245 million and potential milestone payments...

BRIEF-Crispr Therapeutics Reports Q1 Results, Provides Business Update

* CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS

BRIEF-Crispr Therapeutics And Vertex Announce FDA Fast Track Designation For CTX001 For Treatment Of Beta Thalassemia

* CRISPR THERAPEUTICS AND VERTEX ANNOUNCE FDA FAST TRACK DESIGNATION FOR CTX001 FOR THE TREATMENT OF BETA THALASSEMIA Source text for Eikon: Further company coverage:

UPDATE 1-Gene therapy stocks plunge after poor trial data

Shares of U.S. gene therapy companies sank on Thursday after drugs developed by two small firms failed to show promise in separate clinical trials, underscoring the challenges in an emerging, lucrative field of biotech.

Sangamo Therapeutics shares dive after poor early-stage trial data

Sangamo Therapeutics Inc's shares sank 27 percent on Thursday after its gene-editing drug failed to show promise in an early-stage trial testing it in patients with ultra-rare disorders.

UPDATE 2-U.S. appeals court upholds MIT, Harvard patents on CRISPR gene editing

A U.S. appeals court on Monday allowed a research center affiliated with the Massachusetts Institute of Technology and Harvard University to keep patents potentially worth billions of dollars on a groundbreaking gene editing technology known as CRISPR.

UPDATE 2-CRISPR gene editing can cause risky collateral DNA damage - study

Scientists studying the effects of the potentially game-changing gene editing tool CRISPR/Cas9 have found it can cause unexpected genetic damage which could lead to dangerous changes in some cells.

BRIEF-Crispr Therapeutics Reports Q1 Loss Per Share $0.62

* CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Crispr Therapeutics Qtrly collaboration Revenue $32.3 Mln

* CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

UPDATE 2-Sangamo in $3 billion gene-editing deal with Gilead

* Sangamo stock jumps 21 percent (Adds CEO and executive quotes, background, updates share price)

BRIEF-Crispr Therapeutics Says Public Offering Of 5 Mln Common Shares Priced At $22.75/Share

* CRISPR THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON SHARES

BRIEF-Crispr Therapeutics ‍Commences Public Offering Of $100 Mln Common Shares​

* CRISPR THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES

BRIEF-Crispr Therapeutics Announces Appointment Of Dr. Rodger Novak As Chairman Of The Board

* CRISPR THERAPEUTICS ANNOUNCES APPOINTMENT OF DR. RODGER NOVAK AS CHAIRMAN OF THE BOARD

BRIEF-Vertex, CRISPR Therapeutics To Co-Develop CTX001 As CRISPR/Cas9 Gene Edited Treatment

* VERTEX AND CRISPR THERAPEUTICS TO CO-DEVELOP AND CO-COMMERCIALIZE CTX001 AS CRISPR/CAS9 GENE EDITED TREATMENT FOR SICKLE CELL DISEASE AND Β-THALASSEMIA

BRIEF-CRISPR Therapeutics Submits First Clinical Trial Application For CRISPR Gene-Edited Therapy, In Β-Thalassemia

* CRISPR THERAPEUTICS SUBMITS FIRST CLINICAL TRIAL APPLICATION FOR A CRISPR GENE-EDITED THERAPY, CTX001 IN Β-THALASSEMIA

BRIEF-CRISPR Therapeutics appoints Michael Tomsicek as CFO

* CRISPR Therapeutics announces appointment of Michael Tomsicek as Chief Financial Officer

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up